What Clor Treats: Main Uses and Benefits

Clor, which contains the anti-infective agent Clarithromycin, is applied across domains where additional symptomatic support is needed to manage bacterial infections.

The medication is commonly used to help with symptomatic management of infections affecting the airways, such as community-acquired pneumonia (CAP) and acute bacterial exacerbations of chronic bronchitis, as well as infections leading to localized pain in the ears and sinuses, like acute otitis media and acute maxillary sinusitis. It also plays a specialized role in combination therapy for H. pylori and is used for managing H. pylori in situations where prevention of duodenal ulcer recurrence is the goal. It is considered relevant as an alternative when a patient has a known penicillin allergy.

It is relevant for easing symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms.

It is used in situations involving certain distressing symptoms like fever, persistent cough, and inflammation, providing supportive relief when symptoms interfere with routine activities and functional stability.

---

Fact Box: Support for Symptoms Related to Infection

Clor is commonly used across conditions presenting with acute episodes where symptoms are related to systemic imbalance (like fever) and inflammatory or irritative states (like painful sinus or throat congestion), offering symptomatic relief that helps patients cope more steadily with symptom fluctuations.

Regulatory References

1. U.S. National Institutes of Health (NIH) DailyMed

The eligibility for Clor (Clarithromycin) is strictly defined by regulatory bodies, outlining allowed, restricted, and prohibited populations.

Populations with Absolute Contraindications

Use of Clor is prohibited for patients with:

• A known hypersensitivity to Clarithromycin, Erythromycin, or any other macrolide antibiotic.
• A history of QT prolongation or ventricular cardiac arrhythmias.
• Severe hepatic failure combined with renal impairment.
• History of cholestatic jaundice or hepatic dysfunction associated with prior Clarithromycin use.
• Concomitant use with certain medications, including lovastatin, simvastatin, ergotamine, pimozide, cisapride, or lurasidone.

Age and Condition-Based Eligibility

• Age: Clor tablets are indicated for adults and children 12 years and older. The oral suspension is used for children aged 6 months to 12 years. Safety and efficacy are not established in infants under 6 months.
• Organ Function: Patients with severe renal impairment (creatinine clearance < 30 mL/min) are eligible only if the dose is reduced by one-half. Caution is advised in patients with impaired hepatic function alone.
• Pregnancy and Lactation: Use during pregnancy is generally not recommended unless the benefit outweighs the risk. Use in nursing mothers should be avoided as the medicine passes into breast milk.

Interactions with other medicines and products

The official regulatory profile for Clor, containing Clarithromycin, establishes mandatory restrictions and administration requirements based on documented drug interactions. The pharmacokinetic interactions are primarily due to Clarithromycin's classification as an inhibitor of the CYP3A4 enzyme and the P-glycoprotein (P-gp) efflux transporter. This documented mechanism leads to reduced clearance and increased plasma concentrations of numerous co-administered medicines.

Formal Regulatory Constraints

Co-administration is contraindicated with several medicines due to the high risk of severe toxicity or adverse events. These include Lovastatin and Simvastatin (risk of rhabdomyolysis), Pimozide (risk of QT prolongation), Ergotamine and Dihydroergotamine (risk of acute ergotism), Ticagrelor, and Ranolazine. The contraindication with Colchicine is specific to patients with pre-existing hepatic or renal impairment.

Pharmacodynamic interactions are also documented, such as an additive effect with other QT-prolonging drugs, and the potential for severe hypoglycemia when co-administered with certain oral hypoglycemic agents or insulin. A mandatory timing rule requires that Clarithromycin tablets be administered at least 4 hours apart from Zidovudine to prevent reduced Zidovudine absorption. The extended-release tablet formulation is noted to have increased absorption (AUC) when taken with food, a specific interaction restriction documented in regulatory labeling.

How Clor Works

Clarithromycin's mechanism acts as an inhibitor by selectively binding to the bacterial 50S ribosomal subunit, specifically the 23S ribosomal RNA. This molecular interaction physically blocks the peptide exit tunnel, which prevents the process of translocation and halts the assembly of proteins necessary for the continuation of the bacterial life cycle. This primary molecular domain results in a bacteriostatic effect, the functional consequence of inhibited cellular replication.

This mechanism is augmented by its active derivative, 14-hydroxyclarithromycin, which retains the capacity to inhibit ribosomal assembly. This metabolic pathway results in synergistic activity between the parent compound and the metabolite, contributing to the overall magnitude of the drug’s pharmacodynamic effect.

However, the mechanism is constrained by bacterial counter-adaptations, such as the expression of efflux pumps (which actively expel the drug) or enzymes that cause ribosomal methylation (which decreases binding affinity at the target site). These factors directly limit the efficacy of ribosomal blockade, potentially leading to a physiological failure to inhibit bacterial growth in resistant strains.

Administration and Dosing Principles

Clor, containing the active substance Clarithromycin, is administered via two approved routes: oral and intravenous (IV) infusion. Oral forms include immediate-release tablets, extended-release tablets, and a suspension reconstituted from granules. The IV formulation is restricted to a specialized setting and must be administered as a slow infusion over 60 minutes; it should not be given as a bolus or intramuscular injection.

---

Dosage and Scheduling

Standard adult dosing for the immediate-release tablet is typically 250 mg to 500 mg taken twice daily. The extended-release tablet, designed for once-daily use, is prescribed at a total dose of 1000 mg. Treatment course duration for most applications spans 7 to 14 days, though specific infection types may mandate a minimum of 10 days.

Administration Conditions

Intake conditions vary by formulation: the immediate-release tablets and oral suspension may be taken with or without food. However, the extended-release tablets must be taken with food and require that they be swallowed whole without being crushed or chewed to maintain their controlled-release mechanism.

Population-Specific Use

For pediatric patients over six months of age, the oral suspension is the standard form, with dosing calculated based on body weight. A dose modification is necessary for adults with severe renal impairment (creatinine clearance below 30 mL/min); in this population, the total daily dosage must be reduced by 50%.

Research Evidence / Overview of Studies for Clor (Clarithromycin)

Evidence for Conditions Involving Acute Airway Symptoms

The research into Clor's use for managing acute airway conditions like Community-Acquired Pneumonia (CAP) and Acute Bacterial Exacerbations of Chronic Bronchitis primarily involves Randomized Controlled Trials (RCTs) and comprehensive Meta-analyses. These studies were conducted during periods of increased symptom activity to examine the use of Clor in addition to standard care. Researchers monitored a range of outcomes related to systemic or functional imbalance, such as outcomes describing episodic or acute changes, how symptoms like fever and cough were monitored over the study period, and the rate of hospitalization. What remains uncertain is the full influence of evolving antimicrobial resistance patterns on the consistency of findings.

---

Evidence for Multi-Drug Regimens in H. pylori Management

Clor was evaluated in multi-drug regimens—often called "triple therapy"—to target the H. pylori bacterium, a factor relevant for monitoring duodenal ulcer recurrence. The evidence base consists mostly of RCTs that specifically research examined the microbiological clearance rates of the bacterium. The main outcomes measured included the microbiological clearance rates and the subsequent monitoring of duodenal ulcer recurrence. The primary limitation is the rapidly increasing rate of clarithromycin resistance globally, which means findings describe group patterns, not personal outcomes and may vary by location.

---

Long-Term Research and Follow-up Intervals

The majority of clinical trials for Clor focus on assessing episodic or acute changes and research exploring short-term symptom changes over the course of treatment, typically lasting 5 to 14 days. The exception is the H. pylori research, where studies often included long-term follow-up to monitor duodenal ulcer recurrence. For most other infections, long-term outcomes are not well characterized in the research, and limited information is available regarding the risk of late recurrence beyond defined time intervals.

---

Scientific Uncertainties and Research Gaps

Studies show that the consistency of study findings is challenged by the global variation and increase in antimicrobial resistance to macrolides. This resistance can lead to mixed findings when the drug is evaluated in different geographical regions. Furthermore, comparative evidence is lacking in some areas when attempting to directly compare Clor against the newest available antibiotic classes. Subgroup findings are uncertain when specific populations have not been the focus of dedicated large-scale trials.

Key Studies & References

1. Clarithromycin Tablet, Film Coated [U.S. National Institutes of Health (NIH) DailyMed Drug Label]
2. Macrolide Antibiotics (MedlinePlus - General Overview)

Common questions about Clor (FAQ)

Q: What specific conditions or symptoms is Clor approved to treat?

A: Official regulatory documents confirm that Clor is approved to treat specific bacterial infections, including certain types of pneumonia, bronchitis, and infections of the sinuses, skin, and throat. The drug is also used alongside other medicines as part of a regimen to treat and eliminate the bacterium H. pylori.

Q: Is Clor generally intended to cure a condition or to help manage symptoms?

A: The mechanism of action described in official documents classifies Clor's active substance as a bacteriostatic agent. This means the drug works primarily by stopping the growth and replication of susceptible bacteria.

Q: How quickly does Clor typically begin to work after starting treatment?

A: Studies examining the drug’s pharmacokinetics indicate that peak concentrations in the blood are generally reached approximately 2 to 3 hours after taking an oral dose. However, it typically takes 3 to 4 days of consistent dosing for the medicine to reach stable, continuous levels in the body, which is referred to as a steady state.

Q: Is Clor a controlled substance or a Schedule drug?

A: Clor is a prescription-only medicine that belongs to the macrolide antibiotic class. According to regulatory classifications, it is not listed as a controlled substance under the U.S. Drug Enforcement Administration’s scheduling system.

Q: Does Clor cause long-term side effects according to official documents?

A: Official safety documents do specify a long-term risk for a certain patient population. A pattern has been observed showing an increased risk of all-cause mortality (death from any cause) in patients with established Coronary Artery Disease ( CAD) one year or more after they completed treatment.

Q: Does Clor carry any warnings about mental or mood changes?

A: Regulatory information notes that the drug may have potential Nervous System effects, including dizziness, confusion, and disorientation. If these symptoms are experienced, they are classified as potential side effects.

Q: What is the information on using alcohol while taking Clor?

A: Official prescribing information does not list a specific formal contraindication or interaction warning between Clor and moderate alcohol consumption. This is generally consistent with maintaining a normal diet and habits unless specific guidance is provided by a healthcare professional.

Q: Can Clor interact with common over-the-counter pain relievers?

A: There is no formal pharmacokinetic interaction noted with all over-the-counter pain relievers. However, Clor carries warnings about potential liver dysfunction. The potential for liver-related warnings in both medication categories is a factor noted in safety documents.

Q: Can older adults or the elderly population generally use Clor?

A: Clor is used in the elderly population, but specific warnings are included in regulatory documents. Official prescribing information indicates that older patients may be more susceptible to certain effects, such as drug-associated changes to the QT interval, a cardiac rhythm concern.

Q: What is the high-level difference between Clor and other similar medicines in the same class?

A: The key difference described in regulatory documents relates to the drug’s metabolic process. Clor's active ingredient is classified as a potent inhibitor of the CYP3A4 enzyme, which is a major factor that can significantly increase the concentration of many co-administered prescription medicines.

Q: Does Clor interact with birth control medications?

A: Authoritative public health and regulatory sources indicate that Clor is generally not expected to interfere with the effectiveness of hormonal forms of contraception.

Q: Does Clor have a known effect on a person's ability to drive or operate machinery?

A: Official safety information notes that side effects such as dizziness, confusion, and disorientation have the potential to affect a person's ability to safely drive or operate machinery.

Q: What information is available regarding stopping the use of Clor?

A: Regulatory guidance states that the full prescribed course of therapy is highly recommended to reduce the risk of antimicrobial resistance. The label indicates immediate cessation of the drug is required if severe reactions, such as hypersensitivity or liver injury, occur.

Q: What is the general relationship between patient age and the risk of side effects with Clor?

A: Regulatory data specifically indicates that elderly patients may exhibit increased susceptibility to drug-associated effects on the QT interval. This means that age is a factor that may influence the risk of certain serious side effects.

Q: Does the official information mention any restrictions on common beverages like coffee or juice when taking Clor?

A: Official prescribing information does not list any restrictions on drinking common beverages such as coffee or juice, which is consistent with maintaining a normal diet.

Q: What is the relevance of consistent timing when taking Clor for the overall treatment plan?

A: Pharmacokinetic data used for establishing dosing is based on regular intervals (e.g., every 12 hours) and demonstrates that stable drug levels (steady-state) are achieved over a few days. This pharmacokinetic data suggests that maintaining a regular schedule supports the achievement and maintenance of the drug's desired stable therapeutic levels.

Q: Is there a possibility of developing tolerance to Clor over time?

A: Official regulatory information addresses the risk of bacteria developing resistance (antimicrobial resistance) to the drug if therapy is stopped early. However, the label does not discuss the development of individual patient 'tolerance' to the drug's effects over time.

Q: Is the active ingredient in Clor available in a generic formulation?

A: Yes, the active ingredient in Clor, Clarithromycin, is available in the form of multiple generic products that have been approved by the FDA following the expiration of the original patent protections.

Q: Are clinical trials for Clor still ongoing or accepting participants?

A: Research into the drug's active substance is continuous. National clinical trial registries list ongoing studies that are examining the use of the drug for conditions that extend beyond its current approved indications.

How to Store and Dispose of Clor (Clarithromycin)

The storage of Clor is mandated by regulatory bodies to ensure product stability, with specific rules based on the formulation.

Tablets and unmixed granules must be kept at controlled room temperature (typically 20 C to 25 C), protected from light and excessive moisture. The mixed oral suspension must not be refrigerated or frozen and must be discarded after 14 days.

All forms must remain in the original, tightly closed container and strictly out of the sight and reach of children.

Disposal instructions require that unused or expired Clor not be thrown into household waste or flushed down the drain. The product must be disposed of through an authorized drug take-back program or in accordance with local national regulations.